On November 6, 2025, Opus Genetics, Inc. announced a $23 million direct offering and a successful Type B meeting with the FDA for their gene therapy candidate OPGx-LCA5. The FDA provided positive feedback on their registration strategy for treating Leber congenital amaurosis, supporting their ongoing clinical trial expectations.